Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist?

Mitsuhiro Akiyama1, Waleed Alshehri1, Yuko Kaneko1

  • 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Autoimmunity Reviews
|December 12, 2023
PubMed

Insights

Early rheumatoid arthritis (RA) treatment is key for joint health. Achieving RA remission may also prevent lung fibrosis progression in RA-associated interstitial lung disease (RA-ILD).

Area of Science:

  • Rheumatology
  • Pulmonology
  • Immunology

Background:

  • Rheumatoid arthritis (RA) is an autoimmune disease causing chronic synovitis and joint destruction.
  • Molecular targeted therapies and treat-to-target strategies improve daily life for RA patients.
  • Interstitial lung disease (ILD) is a serious extra-articular complication impacting RA prognosis.

Purpose of the Study:

  • To review clinical and radiological features of RA-ILD.
  • To discuss current and emerging treatment strategies for RA-ILD.
  • To highlight the importance of early intervention for both joint and lung outcomes in RA.

Main Methods:

  • Literature review of recent advancements in RA and RA-ILD management.
  • Analysis of clinical and radiological data for RA-ILD.
  • Synthesis of evidence regarding disease behavior and progression patterns.

Main Results:

  • Early RA diagnosis and treatment are crucial for joint outcomes.
  • Achieving RA remission is vital for preventing pulmonary fibrosis progression in RA-ILD.
  • RA-ILD exhibits diverse disease behaviors, necessitating further research.

Conclusions:

  • A 'window of opportunity' exists for managing both RA joints and RA-ILD.
  • Understanding RA-ILD heterogeneity is critical for personalized treatment.
  • Further evidence is needed to accurately determine RA-ILD disease behavior and optimize management.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.9K
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
240
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
244
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
450